Ordering
Available Variants10 mg
CHA.66745-10mg
Price
€89.60
Available – Dispatch in 14 days
50 mg
CHA.66745-50mg
Price
€362.40
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.66745-10mg | €89.60 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.66745-50mg | €362.40 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C24H29ClN6O3 |
|---|---|
| CAS Number | 2166387-65-9 |
| Molecular Weight | 484.98 |
| MDL number | MFCD31692350 |
| NACRES | NA.28 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
BI-3802, also known by its CAS number 2166387-65-9, is a small molecule inhibitor that has been investigated for its potential therapeutic applications. This compound has been shown to exhibit inhibitory activity against specific biological targets, which are implicated in various disease pathways. The mechanism of action of BI-3802 involves binding to and modulating the activity of these targets, thereby altering downstream signaling events. As a result, BI-3802 has been explored as a potential treatment option for certain diseases, including those related to inflammation and immune responses. Further research is needed to fully elucidate the pharmacological properties and potential clinical benefits of BI-3802, but preliminary studies suggest that it may have a favorable safety and efficacy profile, warranting continued investigation into its therapeutic potential. Additional studies are required to fully characterize the effects of BI-3802.
